混合免疫疗法显示,在脑转移的黑素瘤患者中,长期疾病控制率超过50%。 Combination immunotherapy shows over 50% long-term disease control in melanoma patients with brain metastases.

一项新的研究表明,混合使用免疫疗法药物可以大大提高患黑瘤病人的存活率,这些病人的癌症已经蔓延到大脑。 A new study shows that a combination of immunotherapy drugs can significantly improve survival rates for melanoma patients with cancer that has spread to the brain. 为期七年的临床试验后续调查显示,50%以上接受这种结合治疗的患者实现了长期疾病控制。 The seven-year follow-up of a clinical trial revealed that over 50% of patients treated with this combination achieved long-term disease control. 这比过去16周的存活率有了重大改善。 This is a major improvement from the previous 16-week survival rate. 该研究报告发表在《柳叶刀肿瘤学》中,它建议混合免疫疗法应成为这类病人的标准治疗方式。 The study, published in the Lancet Oncology, suggests that combination immunotherapy should become the standard treatment for such patients.